Navidea to Host Moderated Q&A Webcast with Management
June 14 2018 - 5:37PM
Business Wire
Navidea Biopharmaceuticals (NYSE MKT: NAVB) (Navidea or The
Company), a company focused on the development of precision
immunodiagnostic agents and immunotherapeutics, announced today
that it will hold an online Question & Answer (Q&A) Session
focused on Navidea’s clinical progress in Nonalcoholic
Steatohepatitis (NASH) with Jed Latkin, Chief Financial and
Operating Officer, and Fred Cope, Ph.D., Chief Scientific Officer
of Navidea, on Thursday June 21, 2018 at 5:00 p.m. Eastern Time.
Investors are invited to submit NASH-related questions they would
like to hear answered to ir@navidea.com or tpatel@edisongroup.com
by Wednesday, June 20, 2018.
Event:
Navidea IR Q&A Session – June 2018
Date:
Thursday, June 21, 2018
Time:
5:00 p.m. Eastern Time
Website:
www.navidea.com
For the June IR-focused Q&A Session, Navidea invites all
interested investors to submit questions they would like to see
asked by Wednesday, June 20, 2018 to ir@navidea.com or
tpatel@edisongroup.com.
Details for the webcast link will be made available on the
Investor Relations section of Navidea’s website at
www.navidea.com.
About Navidea Biopharmaceuticals
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a
biopharmaceutical company focused on the development of precision
immunodiagnostic agents and immunotherapeutics. Navidea is
developing multiple precision-targeted products based on its
Manocept™ platform to enhance patient care by identifying the sites
and pathways of disease and enable better diagnostic accuracy,
clinical decision-making, and targeted treatment. Navidea’s
Manocept platform is predicated on the ability to specifically
target the CD206 mannose receptor expressed on activated
macrophages. The Manocept platform serves as the molecular backbone
of Tc 99m tilmanocept, the first product developed and
commercialized by Navidea based on the platform. The development
activities of the Manocept immunotherapeutic platform are being
conducted by Navidea in conjunction with its subsidiary, Macrophage
Therapeutics, Inc. Navidea’s strategy is to deliver superior growth
and shareholder return by bringing to market novel products and
advancing the Company’s pipeline through global partnering and
commercialization efforts.
For more information, please visit http://www.navidea.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180614006296/en/
Navidea BiopharmaceuticalsJed Latkin,
614-551-3416CFO/COOjlatkin@navidea.comorEdison AdvisorsTirth Patel,
646-653-7035tpatel@edisongroup.com
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Apr 2023 to Apr 2024